KOPRANNSEKopran Limited· PharmaceuticalsHighPositive
Announced Thu, 15 May, 2025 · 15:40 IST

Kopran Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 3.00 per equity share.

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹185.01
prior close
₹184.89
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-2.3% vs market

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.4
10m
-1.1
15m
-0.9
30m
-1.1
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-1.5+0.8-2.3
Next day
+1.1+2.0-0.9
2d
+1.3+0.9+0.4
3d
+3.9+1.7+2.2
4d
+1.6+1.6+0.1
5d
+0.5+2.2-1.8
1w
+0.1+2.7-2.6
15d
+4.8+4.5+0.3
1m
+4.6+5.6-1.0
2m
-2.0+9.0-11.0
3m
-15.1+3.5-18.7
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kopran Limited's Board, at its meeting on May 15, 2025, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, along with a recommended Final Dividend of Rs. 3.00 per equity share (30% on face value of Rs. 10), subject to shareholder approval at the 66th AGM. On a consolidated basis, FY25 revenue from operations rose modestly to Rs. 629.60 crore (vs Rs. 614.59 crore in FY24), but profit after tax fell about 24% to Rs. 38.55 crore (vs Rs. 50.96 crore), with EPS at Rs. 7.99 vs Rs. 10.57 earlier. Standalone performance was weaker, with revenue dropping to Rs. 271.01 crore (from Rs. 337.46 crore) and profit falling to Rs. 26.86 crore (from Rs. 34.64 crore). The company also noted a pending scheme of amalgamation of Kopran Laboratories Limited into Kopran Limited, and issued 36,200 equity shares under ESOPs during Q4.

Likely market impact

The Rs. 3 dividend matches last year's payout, signaling a stable but not growing distribution to shareholders. However, the sharp drop in profitability on both consolidated and standalone bases is a concern and may temper positive sentiment around the dividend declaration.